A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival ...

Severe aplastic anemia used to have few options and mortality was high, but a new class of drugs offers some hope. A recent review examined treatment options for aplastic anemia (AA), a hematopoietic ...

GRAND RAPIDS, Mich. — At just 18 years old, Lilly VandenBosch has already faced a lifetime of challenges. Diagnosed with aplastic anemia, a rare blood disorder, at the age of 7, her journey has been ...

Eltrombopag combined with immunosuppressive therapy in pediatric patients with severe aplastic anemia achieved a 54.9% overall response rate at 26 weeks, with a 71.4% response in relapsed/refractory ...

Six adult patients with SAA on our study received allo-CBSCT from December 1998 to January 2002. All patients had previously failed immunosuppressive therapy and had no HLA-matched sibling donor. They ...

A new study from the U.K. examined COVID-19 vaccine efficacy among 175 patients with aplastic anemia and PNH. After a first vaccination, healthy volunteers had a seroconversion rate of 95%, compared ...

—A pilot study of 9 patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria asked them to track their symptoms over a 6-month period. The results were encouraging, suggesting a place for ...

The European Society for Blood and Marrow Transplantation (EBMT), Europe's collaborative peer network of professionals working in the field of stem cell transplantation and cellular therapy, announced ...

Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Patients living with SAA, a rare blood disorder, have limited ...

Please provide your email address to receive an email when new articles are posted on . Prior trials established the role of haploidentical BMT for severe aplastic anemia. Two trials underway have the ...

On the surface, Owen Ho looked fine. But on the inside, it was a different story. Ho, 42, was exhausted. He couldn’t muster up the strength to exercise even though months earlier, six-hour bike rides ...